# Limertinib

Source: https://onco.cc/drugs/limertinib/  
OnCo record `limertinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Limertinib is Aosaikang's third-generation EGFR inhibitor, approved in China in 2024 for lung cancer with the T790M resistance mutation after earlier EGFR drugs, and in phase 3 trials for first-line use.

## Summary

Jiangsu Aosaikang's limertinib (ASK120067) was approved by the NMPA in 2024 for locally advanced or metastatic EGFR T790M-positive non-small cell lung cancer after progression on earlier EGFR inhibitors, joining osimertinib, furmonertinib and befotertinib among China's third-generation options. A phase 3 first-line trial against gefitinib is registered.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Code: ASK120067
- Modality: Oral third-generation EGFR tyrosine kinase inhibitor
- Mechanism: A covalent inhibitor of EGFR sensitising and T790M resistance mutations that spares wild-type EGFR, the osimertinib class.
- Approvals: CN 2024: Locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer after prior EGFR inhibitor therapy

## Sources

- ClinicalTrials.gov: trials of Limertinib: https://clinicaltrials.gov/search?intr=ASK120067

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- trials: [ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC](https://onco.cc/trials/nct04143607/), [ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy](https://onco.cc/trials/nct07109531/)

---
JSON: https://onco.cc/api/v1/entities/limertinib.json